SurgiLight Reports Updated Clinical Trials and Worldwide Market on IR-Laser for Presbyopia Correction.

Business Editors/Health & Medical Writers

ORLANDO, Fla.--(BW HealthWire)--Nov. 20, 2000

SurgiLight Inc., (OTCBB:SRGL) announced today that it has expanded its clinical trial studies of laser presbyopia reversal (LAPR) using its IR-laser in Venezuela, Argentina, Brazil, Bahamas and Japan. The Company also scheduled installation of the IR-laser in some European countries.

As reported earlier, the Company has presented the first 97 cases of presbyopia data in the World Refractive Surgery Symposium in Oct. 19-22 (Dallas, TX). The Company has recently submitted 4 papers to the American Society of Cataracts and Refractive Surgery (ASCRS, May, 2001), where more than 500 cases of LAPR will be presented by ophthalmologists from various countries that are using the Company's IR-laser. They include groups of doctors from Japan, Brazil, Venezuela, Argentina, The Bahamas and U.S.

The Company is in process of obtaining CE-Mark certification and selecting various international distributors. The initial promotional systems in Italy, France and Israel are scheduled to be delivered before the end of the year. The Company plans to submit additional 510(K) applications based on certain 510(K) clearances acquired from Premier Laser Systems.

According to The Wallstreet Journal (Oct. 26, 2000), there are 89 million Americans that have presbyopia with 4 million additional each year. Based on a procedure fee of $4,000 per patient, this shall present a total potential market revenue of over $350 billion. The Company expects to charge a royalty fee of $500 per patient to surgeons who use the Company's IR-3000 system in the U.S. and Europe. The Company projects that at least 3 millions of Americans may accept the laser presbyopia surgery in the first 2-3 years after the procedure is cleared in U.S. In addition, more than 5 million international presbyopic patients are estimated to accept the procedure between the years 2001 to 2005.

The Company believes that its IR-laser technology and clinical data for presbyopia correction are at least 2 to 3 years ahead of its competitors and has the advantages in penetrating the worldwide market which is estimated to be over $1.5 trillion based on a presbyopia population of over 900 million. The Company currently owns 15 granted patents and 18 pending patents in IR-laser technology and its applications in ophthalmic surgeries.

The Company's IR-3000 system is a solid-state "cold" laser and is fundamentally different from the thermal IR-laser made by Sunrise (Nasdaq:SNRS) and the UV excimer lasers made by VISX (Nasdaq:EYE), LaserSight (Nasdaq:LASE), Bausch and Lomb (NYSE:BOL) and Nidek (Japan). The Company believes that IR-3000 is still the only laser currently available for the treatment of presbyopic patients in both eyes. The Sunrise thermal laser is limited to low-hyperopia and mono-vision correction. All other competitors are using excimers for LASIK procedures only. The Company's IR-laser also provides the unique procedure that allows post-LASIK patients who are older than 45 to see both near and far.

SurgiLight is a world leader in the development of ultraviolet lasers and new infrared technologies, a pioneer and inventor of scanning lasers and lasers for presbyopia reversal. The Company continues to receive royalty income from international eye laser centers.

This press release may contain forward-looking statements regarding future events and performance of the Company, which involves risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this press release.